Description

CELETOIN 100 MG (1X100)

Indications

CELETOIN 100 MG is primarily indicated for the management of certain types of seizures, including generalized tonic-clonic seizures and partial seizures in adults and children. It may also be used as an adjunctive therapy in patients with epilepsy who are not adequately controlled with other antiepileptic medications. Additionally, CELETOIN is utilized in the treatment of neuropathic pain and may be prescribed for other off-label uses as determined by a healthcare provider.

Mechanism of Action

CELETOIN, which contains the active ingredient phenytoin, exerts its antiepileptic effects through the stabilization of neuronal membranes. It does this by inhibiting the influx of sodium ions during the action potential, thereby reducing the excitability of neurons. This mechanism helps to prevent the spread of seizure activity within the brain. The drug also influences neurotransmitter release, which contributes to its efficacy in controlling seizures.

Pharmacological Properties

CELETOIN is classified as an anticonvulsant medication. It is well-absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 1 to 2 hours after oral administration. The drug is highly protein-bound, primarily to albumin, and has a half-life ranging from 22 to 36 hours, which can vary based on individual metabolic rates. CELETOIN undergoes hepatic metabolism, primarily by cytochrome P450 enzymes, and its metabolites are excreted in the urine.

Contraindications

CELETOIN is contraindicated in patients with a known hypersensitivity to phenytoin or any of its components. Additionally, it should not be used in individuals with a history of acute intermittent porphyria, a condition that affects the production of heme. Caution is advised when prescribing CELETOIN to patients with liver disease, as hepatic impairment can affect drug metabolism and increase the risk of toxicity.

Side Effects

Common side effects associated with CELETOIN include dizziness, drowsiness, and gastrointestinal disturbances such as nausea and vomiting. Other potential side effects may include ataxia, slurred speech, and rash. Long-term use of CELETOIN may lead to more severe adverse effects, including gingival hyperplasia, hirsutism, and vitamin D deficiency. Rare but serious side effects include Stevens-Johnson syndrome and toxic epidermal necrolysis, which require immediate medical attention.

Dosage and Administration

The recommended starting dose of CELETOIN for adults is typically 100 mg taken orally three times daily, with adjustments made based on clinical response and plasma drug levels. For children, the dosage is usually calculated based on body weight, with a common starting dose of 5 mg/kg/day divided into multiple doses. It is crucial to follow the prescribing physician’s instructions and to not discontinue the medication abruptly, as this may precipitate seizures.

Interactions

CELETOIN has the potential to interact with several medications, which may alter its effectiveness or increase the risk of side effects. Drugs that can affect phenytoin levels include anticoagulants, corticosteroids, and certain antidepressants. Additionally, medications that induce or inhibit cytochrome P450 enzymes can significantly impact the metabolism of CELETOIN. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Before initiating treatment with CELETOIN, a thorough medical history should be obtained, and a physical examination should be conducted. Special precautions should be taken in patients with a history of cardiac arrhythmias, diabetes, or renal impairment. Regular monitoring of serum phenytoin levels is recommended to ensure therapeutic efficacy and to minimize the risk of toxicity. Patients should also be advised to maintain adequate dental hygiene to prevent gingival hyperplasia.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of CELETOIN in controlling seizures in patients with epilepsy. A randomized controlled trial published in the Journal of Neurology found that patients receiving phenytoin had a significant reduction in seizure frequency compared to those receiving a placebo. Another study indicated that CELETOIN is effective as an adjunctive therapy in patients with refractory epilepsy, highlighting its role in improving overall seizure control. Ongoing research continues to explore the long-term effects and safety profile of CELETOIN in diverse patient populations.

Conclusion

CELETOIN 100 MG is a well-established medication for the management of seizures and certain neuropathic pain conditions. Its mechanism of action, pharmacological properties, and clinical efficacy have been extensively studied, making it a valuable option for patients with epilepsy. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Regular monitoring and patient education play crucial roles in optimizing treatment outcomes with CELETOIN.